FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:225-226 July 20, 2000 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

To the Editor: Sirolimus is a new, highly potent immunosuppressive drug^1,2 that was recently licensed in the United States and is currently being evaluated in phase 3 clinical trials in Europe. The main side effects of sirolimus are thrombocytopenia and hyperlipidemia.¹ In one study, the frequency of pneumonia was higher in patients receiving sirolimus than in patients receiving cyclosporine. The pneumonia was considered to be of infectious origin, but the overall rate of infection in the sirolimus group was not increased.³ We report three cases of sirolimus-induced interstitial pneumonitis in renal-transplant recipients who were receiving sirolimus as immunosuppressive therapy (trough . . . [Full Text of this Article]

References

Related Letters:

Interstitial Pneumonitis Associated with Sirolimus Therapy in Renal-Transplant Recipients
Singer S. J., Tiernan R., Sullivan E. J., Morelon E., Stern M., Kreis H.
Extract | Full Text  
N Engl J Med 2000; 343:1815-1816, Dec 14, 2000. Correspondence

This article has been cited by other articles:

• Lyster, H., Leaver, N., Hamour, I., Palmer, A., Banner, N. R. (2009). Transfer from ciclosporin to mycophenolate-sirolimus immunosuppression for chronic renal disease after heart transplantation: safety and efficacy of two regimens. Nephrol Dial Transplant 0: gfp386v1-gfp386 [Abstract] [Full Text]  
• Fishman, J. A. (2007). Infection in Solid-Organ Transplant Recipients. NEJM 357: 2601-2614 [Full Text]  
• Taylor, J. L., Palmer, S. M. (2006). Critical Care Perspective on Immunotherapy in Lung Transplantation. J Intensive Care Med 21: 327-344 [Abstract]  
• Nguyen-Van-Tam, J S (2006). Influenza related hospital admissions in children: evidence about the burden keeps growing but the route to policy change remains uncertain. Arch. Dis. Child. 91: 5-7 [Full Text]  
• Nayak, S. K., Jeloka, T. K., Sreepada, S. V. (2004). Sirolimus-induced pneumonitis, sinusitis and macular oedema. Nephrol Dial Transplant 19: 2931-2931 [Full Text]  
• Vlahakis, N. E., Rickman, O. B., Morgenthaler, T. (2004). Sirolimus-Associated Diffuse Alveolar Hemorrhage. Mayo Clin Proc. 79: 541-545 [Abstract]  
• Morelon, E., Mamzer-Bruneel, M.-F., Peraldi, M.-N., Kreis, H. (2001). Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation. Nephrol Dial Transplant 16: 18-20 [Full Text]  
• Singer, S. J., Tiernan, R., Sullivan, E. J., Morelon, E., Stern, M., Kreis, H. (2000). Interstitial Pneumonitis Associated with Sirolimus Therapy in Renal-Transplant Recipients. NEJM 343: 1815-1816 [Full Text]